Evaluating barriers to bioavailability in vivo: validation of a technique for separately assessing gastrointestinal absorption and hepatic extraction.
OBJECTIVE
The purpose of this study was to develop and validate a method for separately evaluating the roles of gastrointestinal absorption and hepatic extraction as barriers to oral bioavailability (BA). The method was validated using five reference compounds known to have different absorption and hepatic extraction properties. Dose-dependence was also investigated for one reference compound.


METHODS
Five reference compounds, amoxicillin, antipyrine, atenolol, propranolol, and testosterone, were administered as a cassette intravenouly (IV), via the hepatoportal vein (IPV), intraduodenally (ID), and intracolonically (IC) to male Sprague-Dawley rats. Blood samples were taken at nine time points, and the compounds were extracted from plasma using solid phase extraction. Plasma concentrations of each compound were determined using Liquid Chromatography Tandem Mass Spectrometry (LC/MS/MS). Pharmacokinetic parameters including bioavailability were calculated for each compound for each route of administration.


RESULTS
Testosterone BA was less than 10% by ID, IC, and IPV routes, due to high hepatic extraction, consistent with its high systemic clearance (63 ml x min(-1) x kg(-1)) and short terminal plasma half-life (23 min). The IPV BA of amoxicillin was 95%+/-6% indicating the absence of hepatic extraction in the rat, but with an ID BA of approximately 39% suggesting incomplete GI absorption to be the main barrier to bioavailability. Absorption was poor from the colon, demonstrating site-dependence consistent with literature reports of site-dependent absorption. Low oral BA of propranolol was due in part to first-pass hepatic extraction (IPV BA of 36%). The IPV BA of propranolol was dose-dependent, most likely due to saturation of the P450 enzymes. Atenolol was incompletely bioavailable due to incomplete intestinal absorption, with no contribution of hepatic first-pass metabolism. Antipyrine was highly bioavailable by all routes.


CONCLUSIONS
This in vivo rat model is demonstrated to be useful for identifying and quantifying the causes of incomplete bioavailabilty. It separately evaluates intestinal absorption, hepatic extraction, and site-dependent absorption. Concentration-dependence of saturable processes can also be examined.
Letendre
Laura
L
Adsorption Systems, Exton, Pennsylvania 19341, USA. laura.letendre@avantixlabs.com
Scott
Mark
M
Dobson
Glenn
G
Hidalgo
Ismael
I
Aungst
Bruce
B
D000658:Amoxicillin / Q000097:blood / Q000493:pharmacokinetics; D000818:Animals; D000983:Antipyrine / Q000097:blood / Q000493:pharmacokinetics; D019540:Area Under Curve; D001262:Atenolol / Q000097:blood / Q000493:pharmacokinetics; D001682:Biological Availability; D041981:Gastrointestinal Tract / Q000378:metabolism*; D007408:Intestinal Absorption; D008099:Liver / Q000378:metabolism*; D008297:Male; D023421:Models, Animal; D011433:Propranolol / Q000097:blood / Q000493:pharmacokinetics; D051381:Rats; D017207:Rats, Sprague-Dawley; D013739:Testosterone / Q000097:blood / Q000493:pharmacokinetics
D013739:Testosterone; D001262:Atenolol; D000658:Amoxicillin; D011433:Propranolol; D000983:Antipyrine